Latanoprost 0.05 MG/ML Ophthalmic Solution — RxCUI 314072
RxNorm drug concept · Semantic clinical drug
RxCUI 314072
Semantic clinical drug · SCD
● Current RxNorm concept 18 FDA products
20 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI314072
Official nameLatanoprost 0.05 MG/ML Ophthalmic Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslatanoprost 0.005 % Ophthalmic Solution; latanoprost 125 MCG per 2.5 ML Ophthalmic Solution
FDA products mapped18
Package NDCs mapped20
Reported Medicaid activity (SDUD)879,118 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Latanoprost Ophthalmic: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- The timing matters because latanoprost reaches its maximum pressure-lowering effect about 8 to 12 hours after you put in the drop. Using it in the evening means peak effectiveness...
- Why does my doctor want me to use these drops in the evening?
- Yes, this is a known and important effect of latanoprost. It can gradually make the iris — the colored part of your eye — more brown over time, especially if your eyes are a mixed...
- I noticed my eye color looks different — is that from this medication?
🕸️ Concept Web — How Latanoprost 0.05 MG/ML Ophthalmic Solution Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Latanoprost 0.05 MG/ML Ophthalmic Solution
RxCUI 314072 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Latanoprost
43611IN
-
Latanoprost
-
Brand names 2
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Iyuzeh
2642280BN -
Xalatan
153159BN
-
Iyuzeh
-
Dose forms 8
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Latanoprost Ophthalmic Solution
377441SCDF -
Latanoprost Ophthalmic Product
1162555SCDG -
Latanoprost Ophthalmic Solution [Iyuzeh]
2642283SBDF -
Latanoprost Ophthalmic Solution [Xalatan]
542526SBDF -
Iyuzeh Ophthalmic Product
2642282SBDG -
Xalatan Ophthalmic Product
1186297SBDG -
Ophthalmic Solution
7670DF -
Ophthalmic Product
1151135DFG
-
Latanoprost Ophthalmic Solution
-
Clinical & branded drugs 5
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Latanoprost 0.05 MG/ML
323956SCDC -
Latanoprost 0.05 MG/ML Ophthalmic Solution [Iyuzeh]
2642284SBD -
Latanoprost 0.05 MG/ML Ophthalmic Solution [Xalatan]
542527SBD -
Latanoprost 0.05 MG/ML [Iyuzeh]
2642281SBDC -
Latanoprost 0.05 MG/ML [Xalatan]
542525SBDC
-
Latanoprost 0.05 MG/ML
Showing up to 8 concepts per family — 16 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Latanoprost 0.05 MG/ML
SCDC · 323956 -
Latanoprost Ophthalmic Solution
SCDF · 377441 -
Latanoprost Ophthalmic Product
SCDG · 1162555
Brand-Name Concepts
-
Latanoprost 0.05 MG/ML Ophthalmic Solution [Iyuzeh]
SBD · 2642284 -
Latanoprost 0.05 MG/ML Ophthalmic Solution [Xalatan]
SBD · 542527 -
Latanoprost 0.05 MG/ML [Iyuzeh]
SBDC · 2642281 -
Latanoprost 0.05 MG/ML [Xalatan]
SBDC · 542525 -
Latanoprost Ophthalmic Solution [Iyuzeh]
SBDF · 2642283 -
Latanoprost Ophthalmic Solution [Xalatan]
SBDF · 542526 -
Iyuzeh Ophthalmic Product
SBDG · 2642282 -
Xalatan Ophthalmic Product
SBDG · 1186297 -
Iyuzeh
BN · 2642280 -
Xalatan
BN · 153159
📦 FDA Products & Package NDCs
18 products · 20 package NDCs
20 package NDCs map to RxCUI 314072 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 24208-0463-25 | 1 BOTTLE in 1 CARTON (24208-463-25) / 2.5 mL in 1 BOTTLE | Latanoprost | Bausch & Lomb Incorporated | 2011-03-22 |
| 25021-0001-02 | 1 BOTTLE in 1 CARTON (25021-001-02) / 2.5 mL in 1 BOTTLE | Latanoprost | Sagent Pharmaceuticals | 2025-07-15 |
| 42571-0499-06 | 1 BOTTLE in 1 CARTON (42571-499-06) / 2.5 mL in 1 BOTTLE | Latanoprost | Micro Labs Limited | 2026-01-22 |
| 50090-1920-00 | 1 BOTTLE in 1 CARTON (50090-1920-0) / 2.5 mL in 1 BOTTLE | Latanoprost | A-S Medication Solutions | 2015-07-09 |
| 50090-7062-00 | 2.5 mL in 1 BOTTLE (50090-7062-0) | Latanoprost | A-S Medication Solutions | 2024-01-16 |
| 58151-0419-35 | 1 BOTTLE, DROPPER in 1 CARTON (58151-419-35) / 2.5 mL in 1... | XALATAN | Viatris Specialty LLC | 2024-10-22 |
| 59762-0333-02 | 1 BOTTLE, DROPPER in 1 CARTON (59762-0333-2) / 2.5 mL in 1... | Latanoprost | Mylan Pharmaceuticals Inc. | 2010-11-15 |
| 61314-0547-01 | 1 BOTTLE in 1 CARTON (61314-547-01) / 2.5 mL in 1 BOTTLE | Latanoprost | Sandoz Inc | 2011-01-07 |
| 61314-0547-03 | 3 BOTTLE in 1 CARTON (61314-547-03) / 2.5 mL in 1 BOTTLE | Latanoprost | Sandoz Inc | 2011-01-07 |
| 64980-0516-25 | 1 BOTTLE, DROPPER in 1 CARTON (64980-516-25) / 2.5 mL in 1... | LATANOPROST | Rising Pharma Holdings, Inc. | 2016-09-01 |
| 65862-0872-25 | 1 BOTTLE in 1 CARTON (65862-872-25) / 2.5 mL in 1 BOTTLE | Latanoprost | Aurobindo Pharma Limited | 2019-09-03 |
| 68071-2376-02 | 1 BOTTLE in 1 CARTON (68071-2376-2) / 2.5 mL in 1 BOTTLE | LATANOPROST | NuCare Pharmaceuticals,Inc. | 2021-03-26 |
| 68071-3884-02 | 1 BOTTLE in 1 CARTON (68071-3884-2) / 2.5 mL in 1 BOTTLE | Latanoprost | NuCare Pharmaceuticals, Inc. | 2025-08-13 |
| 68083-0609-01 | 1 BOTTLE in 1 CARTON (68083-609-01) / 2.5 mL in 1 BOTTLE | latanoprost | Gland Pharma Limited | 2024-11-26 |
| 68462-0944-03 | 1 BOTTLE in 1 CARTON (68462-944-03) / 2.5 mL in 1 BOTTLE | latanoprost | GLENMARK PHARMACEUTICALS INC | 2024-11-26 |
| 70069-0421-01 | 1 BOTTLE in 1 CARTON (70069-421-01) / 2.5 mL in 1 BOTTLE | LATANOPROST | Somerset Therapeutics, LLC | 2019-12-03 |
| 70069-0421-03 | 3 BOTTLE in 1 CARTON (70069-421-03) / 2.5 mL in 1 BOTTLE | LATANOPROST | Somerset Therapeutics, LLC | 2019-12-03 |
| 70756-0680-00 | 1 BOTTLE in 1 CARTON (70756-680-00) / 2.5 mL in 1 BOTTLE (7... | Latanoprost Ophthalmic Solution | Lifestar Pharma LLC | 2026-03-01 |
| 71205-0154-25 | 1 BOTTLE in 1 CARTON (71205-154-25) / 2.5 mL in 1 BOTTLE | Latanoprost | Proficient Rx LP | 2018-11-01 |
| 82584-0003-30 | 30 POUCH in 1 CARTON (82584-003-30) / .2 mL in 1 POUCH | IYUZEH | Thea Pharma Inc. | 2023-07-14 |
Observed labelers:
A-S Medication Solutions (2) ·
Sandoz Inc (2) ·
Somerset Therapeutics, LLC (2) ·
Aurobindo Pharma Limited (1) ·
Bausch & Lomb Incorporated (1) ·
Gland Pharma Limited (1)
· +11 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.